Skip to main content
Journal cover image

The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine.

Publication ,  Journal Article
Schmader, K; Gnann, JW; Watson, CP
Published in: J Infect Dis
March 1, 2008

Worldwide, herpes zoster (HZ) affects millions of patients (particularly older adults) annually and causes significant suffering due to acute and chronic pain, or postherpetic neuralgia (PHN). The objective of this article is to explain the rationale for the HZ vaccine by summarizing data on the epidemiology of HZ in the immunocompetent host, with a focus on recent incidence and risk factor studies; to review information on the burden of HZ; and to discuss the challenges of lessening the morbidity of the disease. The incidence and severity of HZ and PHN are highest in older adults. Given the central nervous system damage caused by HZ, the difficulty of adequately treating HZ to prevent PHN, and the intractability of PHN, the advent of the HZ vaccine appears to be a crucial innovation for preventing HZ and PHN.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Infect Dis

DOI

ISSN

0022-1899

Publication Date

March 1, 2008

Volume

197 Suppl 2

Start / End Page

S207 / S215

Location

United States

Related Subject Headings

  • Risk Factors
  • Neuralgia, Postherpetic
  • Middle Aged
  • Microbiology
  • Incidence
  • Humans
  • Herpesvirus 3, Human
  • Herpes Zoster Vaccine
  • Herpes Zoster
  • Analgesics
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Schmader, K., Gnann, J. W., & Watson, C. P. (2008). The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis, 197 Suppl 2, S207–S215. https://doi.org/10.1086/522152
Schmader, Kenneth, John W. Gnann, and C Peter Watson. “The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine.J Infect Dis 197 Suppl 2 (March 1, 2008): S207–15. https://doi.org/10.1086/522152.
Schmader K, Gnann JW, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis. 2008 Mar 1;197 Suppl 2:S207–15.
Schmader, Kenneth, et al. “The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine.J Infect Dis, vol. 197 Suppl 2, Mar. 2008, pp. S207–15. Pubmed, doi:10.1086/522152.
Schmader K, Gnann JW, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis. 2008 Mar 1;197 Suppl 2:S207–S215.
Journal cover image

Published In

J Infect Dis

DOI

ISSN

0022-1899

Publication Date

March 1, 2008

Volume

197 Suppl 2

Start / End Page

S207 / S215

Location

United States

Related Subject Headings

  • Risk Factors
  • Neuralgia, Postherpetic
  • Middle Aged
  • Microbiology
  • Incidence
  • Humans
  • Herpesvirus 3, Human
  • Herpes Zoster Vaccine
  • Herpes Zoster
  • Analgesics